Analysis and risk assessment method fmea/fmeca for the biowaiver procedure

Authors

  • S. Yu. Visych Institute of qualification improvement for pharmacists, Ukraine
  • S. V. Rusanova Institute of qualification improvement for pharmacists, Ukraine https://orcid.org/0000-0002-7001-2643
  • L. M. Andryukova Institute of qualification improvement for pharmacists, Ukraine https://orcid.org/0000-0002-8705-9042
  • A. B. Dorovskyy Institute of qualification improvement for pharmacists, Ukraine

DOI:

https://doi.org/10.24959/uekj.17.38

Keywords:

biowaiver, risk, risk analysis, risk assessment, FMEA/FMECA method, RPN

Abstract

For today there is rich experience of risk management methods application and its principles. Last years risk management is considered to be the most needed in any business-environment.
Aim. To study the use of FMEA/FMECA method for the final stages of overall risk assessment for quality of biowaiver procedure based on biopharmaceutical classification system – BCS (hereinafter – biowaiver procedure) and establishment of risk levels for determination of strategy for their processing and control.
Results. According to FMEA/FMECA methodology were developed original 5-point and 10-point scales for S, O and D scores that were applied for 14 significant risk factors inherent in biowaiver procedure. Based on analysis of potential causes of risk factors, existing measures for their prevention and detection, S, O and D values were determined for each risk factor and RPN values were calculated. In terms of RPN values exceeding limit values, 5 most critical risk factors were identified, developed a control strategy and proposed preventive measures, that would be taken into account when applying biowaiver to confirm equivalence of generic and reference drugs, and would prevent manifestations of causes of nonconformities.
Conclusions. As a result of performed complex of works, an adapted application of FMEA/FMECA method for analysis and risk assessment of biowaiver procedure has become possible. As result of quantitative risk assessment were calculated values of RPN, which, in comparison with limit and critical RPN values, revealed risk factors, causes of which could have the greatest effect on quality of biowaiver procedure. Knowledge of nature of their undesirable manifestation made it possible to reasonably approach the adoption of correct decisions for determination of risk control strategy for biowaiver procedure, and also to ensure its quality with set of preventive actions.

References

ST–N MOZU 42–4.2:2011. Lіkarskі zasoby. Upravlіnnia ryzykamy dlia yakostі (ICH Q9) (2011). Ministerstvo okhorony zdorovia Ukrainy, 30.

Lebedynets, V. O., Kurinna, M. V. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (48), 11–20.

Zupanets, K. O., Ratushna, K. L., Dobrova, V. Ye. (2015). Klinicna farmatsiia – Clinical pharmacy, 3 (19), 4–10.

Yakovenko, V. K. (2014). The study of risks of herbal medicines production by the FMEA–analysis method. Vìsnik farmacìï, 4, 49–52.

Kubbinga, M., Langguth, P., Barends, D. (2013). Risk analysis in bioequivalence and biowaiver decisions.

Biopharmaceutics & Drug Disposition, 34 (5), 254–261. doi: 10.1002/bdd.1831

Vіsych, S. Yu., Rusanova, S. V., Andriukova, L. M. et al. (2016). Vyznachennia osnovnykh faktoriv ryzykiv pry provedenni protsedury bioveiver. Kharkiv : NFaU, 43–44.

Vіsych, S. Yu., Rusanova, S. V., Andriukova, L. M. et al. (2016). Scientific Journal «ScienceRise», 2/2 (16), 51–57.

Vіsych, S. Yu., Rusanova, S. V., Andriukova, L. M. et al. (2016). Formuvannia shkal dlia yakisnoho analizu ryzykiv u protseduri «bioveiver». Ternopil : TDMU, 93–94.

Analysis Techniques for system reliability. Procedures for failure mode and effects analysis (FMEA): IEC 60812, Edition 2.0. (2006). International Electrotechnical Commission (IEC), 93.

Rusanova, S. V., Vіsych, S. Yu., Dorovskyi, O. V. (2017). Efektyvnyi pidkhid do zastosuvannia ekspertnoi otsinky ryzykiv. Kharkіv: NUPh, 147–150.

HOST R 51814.2–2001. Sistemy kachestva v avtomobilestroenii. Metod analiza vidov i posledstvii potentcyalnykh defektov. (2002). IPK Izdatelstvo standartov, 23.

Downloads

Published

2017-11-30

Issue

No. 4(52) (2017)

Section

Quality, standardization and certification in pharmacy

License

Copyright (c) 2017 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:
  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторський договір